The federal government has filed a rebuttal to the Pharmaceutical Research & Manufacturers of America’s argument that drug companies face liability for engaging in truthful speech about “off-label” uses of drugs.
According to the organization’s amicus brief in United States v. Millenium Pharmaceuticals Inc., the government and its relator allege that the manufacturer submitted false claims to the government for Integrilin by circulating articles reprinted from Cardiology, the American Heart Journal and the American Journal of Cardiology about unapproved uses. The federal government, more than 20 states and federal territories and relator Frank Solis have brought claims under the False Claims Act.
